US3480613A
(en)
|
1967-07-03 |
1969-11-25 |
Merck & Co Inc |
2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof
|
US3536809A
(en)
|
1969-02-17 |
1970-10-27 |
Alza Corp |
Medication method
|
US3598123A
(en)
|
1969-04-01 |
1971-08-10 |
Alza Corp |
Bandage for administering drugs
|
US3845770A
(en)
|
1972-06-05 |
1974-11-05 |
Alza Corp |
Osmatic dispensing device for releasing beneficial agent
|
US3916899A
(en)
|
1973-04-25 |
1975-11-04 |
Alza Corp |
Osmotic dispensing device with maximum and minimum sizes for the passageway
|
US4008719A
(en)
|
1976-02-02 |
1977-02-22 |
Alza Corporation |
Osmotic system having laminar arrangement for programming delivery of active agent
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
ES8702440A1
(es)
|
1984-10-04 |
1986-12-16 |
Monsanto Co |
Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
|
IE58110B1
(en)
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
IT1229203B
(it)
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
PH30995A
(en)
|
1989-07-07 |
1997-12-23 |
Novartis Inc |
Sustained release formulations of water soluble peptides.
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
US5026687A
(en)
|
1990-01-03 |
1991-06-25 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
|
JPH05506230A
(ja)
|
1990-04-06 |
1993-09-16 |
ジーンラブス テクノロジイズ インコーポレイテッド |
C型肝炎ウイルスエピトープ
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
DE4207363A1
(de)
|
1992-03-04 |
1993-09-09 |
Max Delbrueck Centrum |
Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
|
US5610054A
(en)
|
1992-05-14 |
1997-03-11 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic RNA molecule targeted against Hepatitis C virus
|
US6423489B1
(en)
|
1992-09-10 |
2002-07-23 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6174868B1
(en)
|
1992-09-10 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6391542B1
(en)
|
1992-09-10 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus-associated diseases
|
US6995146B2
(en)
|
1992-09-10 |
2006-02-07 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
US6433159B1
(en)
|
1992-09-10 |
2002-08-13 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of Hepatitis C virus associated diseases
|
AU680435B2
(en)
|
1992-09-10 |
1997-07-31 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for treatment of hepatitis C virus-associated diseases
|
TW333456B
(en)
|
1992-12-07 |
1998-06-11 |
Takeda Pharm Ind Co Ltd |
A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
CN1078478C
(zh)
|
1993-02-24 |
2002-01-30 |
王瑞駪 |
活性抗病毒聚合物的组成及应用方法
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
WO1995003056A1
(fr)
|
1993-07-19 |
1995-02-02 |
Tokyo Tanabe Company Limited |
Inhibiteur de proliferation du virus de l'hepatite c
|
DE4415539C2
(de)
|
1994-05-03 |
1996-08-01 |
Osama Dr Dr Med Omer |
Pflanzen mit virustatischer und antiviraler Wirkung
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
DE4432623A1
(de)
|
1994-09-14 |
1996-03-21 |
Huels Chemische Werke Ag |
Verfahren zur Bleichung von wäßrigen Tensidlösungen
|
GB9505025D0
(en)
|
1995-03-13 |
1995-05-03 |
Medical Res Council |
Chemical compounds
|
JP3786447B2
(ja)
|
1995-03-31 |
2006-06-14 |
エーザイ株式会社 |
C型肝炎の予防・治療剤
|
WO1997001331A2
(en)
|
1995-06-27 |
1997-01-16 |
Takeda Chemical Industries, Ltd. |
Method of producing sustained-release preparation
|
TW448055B
(en)
|
1995-09-04 |
2001-08-01 |
Takeda Chemical Industries Ltd |
Method of production of sustained-release preparation
|
JP2909418B2
(ja)
|
1995-09-18 |
1999-06-23 |
株式会社資生堂 |
薬物の遅延放出型マイクロスフイア
|
US5980945A
(en)
|
1996-01-16 |
1999-11-09 |
Societe De Conseils De Recherches Et D'applications Scientifique S.A. |
Sustained release drug formulations
|
AU2064297A
(en)
|
1996-02-29 |
1997-09-16 |
Immusol, Inc |
Hepatitis c virus ribozymes
|
US5830905A
(en)
|
1996-03-29 |
1998-11-03 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5633388A
(en)
|
1996-03-29 |
1997-05-27 |
Viropharma Incorporated |
Compounds, compositions and methods for treatment of hepatitis C
|
US5990276A
(en)
|
1996-05-10 |
1999-11-23 |
Schering Corporation |
Synthetic inhibitors of hepatitis C virus NS3 protease
|
US5891874A
(en)
|
1996-06-05 |
1999-04-06 |
Eli Lilly And Company |
Anti-viral compound
|
US6264970B1
(en)
|
1996-06-26 |
2001-07-24 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
US5837257A
(en)
|
1996-07-09 |
1998-11-17 |
Sage R&D |
Use of plant extracts for treatment of HIV, HCV and HBV infections
|
GB9617177D0
(en)
|
1996-08-15 |
1996-09-25 |
Kvaerner H & G Offshore Ltd |
Downhole valve actuation
|
US6419961B1
(en)
|
1996-08-29 |
2002-07-16 |
Takeda Chemical Industries, Ltd. |
Sustained release microcapsules of a bioactive substance and a biodegradable polymer
|
JP3927630B2
(ja)
|
1996-09-27 |
2007-06-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ウイルス感染症の予防・治療剤
|
US5922757A
(en)
|
1996-09-30 |
1999-07-13 |
The Regents Of The University Of California |
Treatment and prevention of hepatic disorders
|
CA2217134A1
(en)
|
1996-10-09 |
1998-04-09 |
Sumitomo Pharmaceuticals Co., Ltd. |
Sustained release formulation
|
HU227742B1
(en)
|
1996-10-18 |
2012-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
EP0839525B1
(en)
|
1996-10-31 |
2004-08-04 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
GB9623908D0
(en)
|
1996-11-18 |
1997-01-08 |
Hoffmann La Roche |
Amino acid derivatives
|
IL119833A
(en)
|
1996-12-15 |
2001-01-11 |
Lavie David |
Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis
|
EP0946169B1
(en)
|
1996-12-20 |
2003-02-26 |
Takeda Chemical Industries, Ltd. |
Method of producing a sustained-release preparation
|
US5891474A
(en)
|
1997-01-29 |
1999-04-06 |
Poli Industria Chimica, S.P.A. |
Time-specific controlled release dosage formulations and method of preparing same
|
US6004933A
(en)
|
1997-04-25 |
1999-12-21 |
Cortech Inc. |
Cysteine protease inhibitors
|
GB9708611D0
(en)
|
1997-04-28 |
1997-06-18 |
Univ Cardiff |
Chemical compounds
|
PL193237B1
(pl)
|
1997-06-30 |
2007-01-31 |
Merz Pharma Gmbh & Co Kgaa |
Pochodne 1-aminoalkilocykloheksanu, kompozycja farmaceutyczna je zawierająca oraz ich zastosowanie
|
WO1999007734A2
(en)
|
1997-08-11 |
1999-02-18 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor peptide analogues
|
DK1058686T3
(da)
|
1998-02-25 |
2007-03-05 |
Univ Emory |
2'-fluornukleosider
|
US6613358B2
(en)
|
1998-03-18 |
2003-09-02 |
Theodore W. Randolph |
Sustained-release composition including amorphous polymer
|
GB9806815D0
(en)
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
KR19990085365A
(ko)
|
1998-05-16 |
1999-12-06 |
허영섭 |
지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
|
US6833361B2
(en)
|
1998-05-26 |
2004-12-21 |
Ribapharm, Inc. |
Nucleosides having bicyclic sugar moiety
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
GB9821058D0
(en)
|
1998-09-28 |
1998-11-18 |
Univ Cardiff |
Chemical compound
|
JP2002536452A
(ja)
|
1999-02-12 |
2002-10-29 |
グラクソ グループ リミテッド |
抗ウイルス剤としての(1R,cis)−4−(6−アミノ−9H−プリン−9−イル)−2−シクロペンテン−1−メタノールのホスホルアミダート、ならびに一、二および三リン酸エステル
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
AU1262001A
(en)
|
1999-11-04 |
2001-05-14 |
Biochem Pharma Inc. |
Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
|
SK11922002A3
(sk)
|
2000-02-18 |
2003-06-03 |
Shire Biochem Inc. |
Použitie analógov nukleozidov na liečenie alebo prevenciu infekcií spôsobených flavivírusom
|
DE60136620D1
(de)
|
2000-04-13 |
2009-01-02 |
Pharmasset Inc |
3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
|
GB0009486D0
(en)
|
2000-04-17 |
2000-06-07 |
Univ Cardiff |
Chemical compounds
|
GB0011203D0
(en)
|
2000-05-09 |
2000-06-28 |
Univ Cardiff |
Chemical compounds
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
CZ301182B6
(cs)
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
|
US7169760B2
(en)
|
2000-07-21 |
2007-01-30 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
AR034127A1
(es)
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
WO2002008251A2
(en)
|
2000-07-21 |
2002-01-31 |
Corvas International, Inc. |
Peptides as ns3-serine protease inhibitors of hepatitis c virus
|
US20030008841A1
(en)
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
CN1133642C
(zh)
|
2000-10-09 |
2004-01-07 |
清华大学 |
核苷5’-硫代磷酰氨基酸酯化合物
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
WO2002060926A2
(en)
|
2000-11-20 |
2002-08-08 |
Bristol-Myers Squibb Company |
Hepatitis c tripeptide inhibitors
|
MXPA03005219A
(es)
|
2000-12-12 |
2003-09-25 |
Schering Corp |
Peptidos diarilicos como inhibidores de ns3-serina proteasa en hepatitis de virus c.
|
WO2002048157A2
(en)
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
|
AU2002230763A1
(en)
|
2000-12-13 |
2008-01-03 |
Bristol-Myers Squibb Pharma Company |
Inhibitors of hepatitis c virus ns3 protease
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
KR20030081343A
(ko)
|
2000-12-15 |
2003-10-17 |
파마셋, 리미티드 |
플라비비리다에 감염 치료용 항바이러스제
|
US7105499B2
(en)
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
ES2532836T3
(es)
|
2001-01-22 |
2015-04-01 |
Merck Sharp & Dohme Corp. |
Derivados de nucleósidos como inhibidores de la ARN polimerasa viral dependiente de ARN
|
IL157478A0
(en)
|
2001-03-01 |
2004-03-28 |
Pharmasset Ltd |
Method for the synthesis of 2', 3'-didehydronucleosides
|
US20040209831A1
(en)
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
GB0112617D0
(en)
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
JP2004534830A
(ja)
|
2001-06-21 |
2004-11-18 |
グラクソ グループ リミテッド |
Hcvにおけるヌクレオシド化合物
|
US7022323B2
(en)
|
2001-06-26 |
2006-04-04 |
Progenics Pharmaceuticals, Inc. |
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection
|
WO2003026675A1
(en)
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
|
AU2002330154A1
(en)
|
2001-09-28 |
2003-04-07 |
Centre National De La Recherche Scientifique |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
US6867185B2
(en)
|
2001-12-20 |
2005-03-15 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2369970A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
CA2370396A1
(en)
|
2002-02-01 |
2003-08-01 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis c inhibitor tri-peptides
|
US7323453B2
(en)
|
2002-02-13 |
2008-01-29 |
Merck & Co., Inc. |
Methods of inhibiting orthopoxvirus replication with nucleoside compounds
|
CA2457528C
(en)
|
2002-02-20 |
2011-07-12 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
|
CA2477741A1
(en)
|
2002-02-28 |
2003-09-04 |
Biota, Inc. |
Nucleotide mimics and their prodrugs
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
JP4312718B2
(ja)
|
2002-05-20 |
2009-08-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
AU2003301959A1
(en)
|
2002-05-20 |
2004-06-03 |
Bristol-Myers Squibb Company |
Substituted cycloalkyl p1' hepatitis c virus inhibitors
|
WO2003099316A1
(en)
|
2002-05-20 |
2003-12-04 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis c virus inhibitors
|
WO2003100017A2
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
JP2005533777A
(ja)
|
2002-06-17 |
2005-11-10 |
メルク エンド カムパニー インコーポレーテッド |
Rna抗ウイルス剤としての炭素環ヌクレオシドアナログ
|
AU2003269890A1
(en)
|
2002-06-21 |
2004-01-06 |
Isis Pharmaceuticals, Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CA2488484A1
(en)
|
2002-06-27 |
2004-01-08 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
CA2490200C
(en)
|
2002-06-28 |
2012-01-03 |
Idenix (Cayman) Limited |
2' and 3'-nucleoside prodrugs for treating flaviviridae infections
|
AU2003248748A1
(en)
|
2002-06-28 |
2004-01-19 |
Idenix (Cayman) Limited |
2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US7608600B2
(en)
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
ES2469569T3
(es)
|
2002-06-28 |
2014-06-18 |
Idenix Pharmaceuticals, Inc. |
Prof�rmacos de nucle�sidos modificados en 2' y 3' para el tratamiento de infecciones de Flaviviridae
|
NZ537662A
(en)
|
2002-06-28 |
2007-10-26 |
Idenix Cayman Ltd |
2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
US20060264389A1
(en)
|
2002-07-16 |
2006-11-23 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
WO2004009020A2
(en)
|
2002-07-24 |
2004-01-29 |
Merck & Co., Inc. |
Pyrrolopyrimidine thionucleoside analogs as antivirals
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
US20040229840A1
(en)
|
2002-10-29 |
2004-11-18 |
Balkrishen Bhat |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
HUE033832T2
(en)
|
2002-11-15 |
2018-01-29 |
Idenix Pharmaceuticals Llc |
2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
|
TWI332507B
(en)
|
2002-11-19 |
2010-11-01 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
JP5116972B2
(ja)
|
2002-12-12 |
2013-01-09 |
イデニクス(ケイマン)リミテツド |
2’−分枝ヌクレオシドの製造方法
|
US7601709B2
(en)
|
2003-02-07 |
2009-10-13 |
Enanta Pharmaceuticals, Inc. |
Macrocyclic hepatitis C serine protease inhibitors
|
AR043006A1
(es)
|
2003-02-12 |
2005-07-13 |
Merck & Co Inc |
Proceso para preparar ribonucleosidos ramificados
|
MXPA05011297A
(es)
|
2003-04-25 |
2006-05-25 |
Gilead Sciences Inc |
Analogos antivirales de fosfonato.
|
US7300924B2
(en)
|
2003-04-25 |
2007-11-27 |
Gilead Sciences, Inc. |
Anti-infective phosphonate analogs
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
WO2005020884A2
(en)
|
2003-05-14 |
2005-03-10 |
Idenix (Cayman) Limited |
Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
|
WO2005020885A2
(en)
|
2003-05-21 |
2005-03-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
|
EP3521297B1
(en)
|
2003-05-30 |
2021-12-22 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
WO2005000864A1
(en)
|
2003-06-19 |
2005-01-06 |
F. Hoffmann-La Roche Ag |
Processes for preparing 4’azido nucleoside derivatives
|
GB0317009D0
(en)
|
2003-07-21 |
2003-08-27 |
Univ Cardiff |
Chemical compounds
|
US20050043266A1
(en)
|
2003-07-25 |
2005-02-24 |
Sumedha Jayasena |
Short interfering RNA as an antiviral agent for hepatitis C
|
WO2005037860A2
(en)
|
2003-10-10 |
2005-04-28 |
Vertex Pharmaceuticals Incoporated |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
GB0401088D0
(en)
|
2004-01-19 |
2004-02-18 |
Univ Cardiff |
Phosphoramidate derivatives
|
JP5198055B2
(ja)
|
2004-03-04 |
2013-05-15 |
カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ |
ウイルス感染治療用薬学的組成物における活性成分として有用なホスホン酸ヌクレオシド、およびそれらを生産するための中間体
|
EP1758453B1
(en)
|
2004-06-15 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
|
CA2571675A1
(en)
|
2004-06-23 |
2006-01-05 |
Idenix (Cayman) Limited |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
EP1773355B1
(en)
|
2004-06-24 |
2014-06-25 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
EP1763531A4
(en)
|
2004-06-28 |
2009-07-01 |
Boehringer Ingelheim Int |
ANALOGUE OF HEPATITIS-C INHIBITING PEPTIDES
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
UA88313C2
(ru)
|
2004-07-27 |
2009-10-12 |
Гилиад Сайенсиз, Инк. |
Фосфонатные аналоги соединений ингибиторов вич
|
WO2006021341A1
(en)
|
2004-08-23 |
2006-03-02 |
F. Hoffmann-La Roche Ag |
Antiviral 4’-azido-nucleosides
|
CN101068828A
(zh)
|
2004-08-27 |
2007-11-07 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的酰基磺酰胺化合物
|
WO2007001406A2
(en)
|
2004-10-05 |
2007-01-04 |
Chiron Corporation |
Aryl-containing macrocyclic compounds
|
JP2008517912A
(ja)
|
2004-10-21 |
2008-05-29 |
メルク エンド カムパニー インコーポレーテッド |
RNA依存性RNAウイルス感染治療用フッ素化ピロロ[2,3−d]ピリミジンヌクレオシド
|
EP1827460A4
(en)
|
2004-12-09 |
2012-03-14 |
Univ Minnesota |
NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
|
JP2008531704A
(ja)
|
2005-02-28 |
2008-08-14 |
ジェネラブズ テクノロジーズ インコーポレーティッド |
ウイルス感染症の治療のための三環式ヌクレオシド化合物
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
JP2008535932A
(ja)
|
2005-03-09 |
2008-09-04 |
イデニクス(ケイマン)リミテツド |
抗ウィルス剤としての非天然塩基を有するヌクレオシド
|
TW200720285A
(en)
*
|
2005-04-25 |
2007-06-01 |
Genelabs Tech Inc |
Nucleoside compounds for treating viral infections
|
WO2006119061A2
(en)
|
2005-05-02 |
2006-11-09 |
Merck & Co., Inc. |
Hcv ns3 protease inhibitors
|
WO2007027248A2
(en)
|
2005-05-16 |
2007-03-08 |
Valeant Research & Development |
3', 5' - cyclic nucleoside analogues for treatment of hcv
|
JP2009513564A
(ja)
|
2005-08-09 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
Rna依存性rnaウイルス感染の治療用のリボヌクレオシド環状アセタール誘導体
|
JP2009504677A
(ja)
|
2005-08-12 |
2009-02-05 |
メルク・エンド・カムパニー・インコーポレーテツド |
新規2’−c−メチル及び4’−c−メチルヌクレオシド誘導体
|
JP2009504704A
(ja)
|
2005-08-15 |
2009-02-05 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗ウイルス4′−置換プロヌクレオチドホスホルアミダート
|
NZ609146A
(en)
|
2005-09-26 |
2014-08-29 |
Gilead Pharmasset Llc |
Modified 4’-nucleosides as antiviral agents
|
EP1968595A4
(en)
|
2005-12-02 |
2014-05-21 |
Univ Yale |
METHOD OF TREATING CANCER AND OTHER CONDITIONS OR SICKNESS CONDITIONS USING L-CYTOSIN NUCLEOSIDE ANALOGS
|
RU2422454C2
(ru)
|
2005-12-09 |
2011-06-27 |
Ф. Хоффманн-Ля Рош Аг |
Антивирусные нуклеозиды
|
US7781576B2
(en)
|
2005-12-23 |
2010-08-24 |
Idenix Pharmaceuticals, Inc. |
Process for preparing a synthetic intermediate for preparation of branched nucleosides
|
CA2637879A1
(en)
|
2006-02-14 |
2007-08-23 |
Merck & Co., Inc. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
WO2007113159A1
(en)
|
2006-04-04 |
2007-10-11 |
F. Hoffmann-La Roche Ag |
3',5'-di-o-acylated nucleosides for hcv treatment
|
US7842672B2
(en)
|
2006-07-07 |
2010-11-30 |
Gilead Sciences, Inc. |
Phosphonate inhibitors of HCV
|
NZ575437A
(en)
|
2006-09-27 |
2012-02-24 |
Coley Pharm Gmbh |
Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
|
ES2358853T3
(es)
|
2006-10-10 |
2011-05-16 |
Medivir Ab |
Inhibidor nucleosídico de vhc.
|
JP5252459B2
(ja)
|
2006-10-10 |
2013-07-31 |
ギリアド ファーマセット エルエルシー |
リボフラノシルピリミジンヌクレオシドの調製
|
GB0623493D0
(en)
|
2006-11-24 |
2007-01-03 |
Univ Cardiff |
Chemical compounds
|
DE602007008616D1
(de)
|
2006-12-11 |
2010-09-30 |
Hoffmann La Roche |
Verfahren zur herstellung von 4'-azidocytidinderivaten
|
CA2672613A1
(en)
|
2006-12-20 |
2008-07-03 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
US20100056468A1
(en)
|
2007-01-08 |
2010-03-04 |
University Health Network |
Pyrimidine Derivatives As Anticancer Agents
|
WO2008100447A2
(en)
|
2007-02-09 |
2008-08-21 |
Gilead Sciences, Inc. |
Nucleoside analogs for antiviral treatment
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2685748A1
(en)
|
2007-05-14 |
2008-11-14 |
Rfs Pharma, Llc. |
Azido purine nucleosides for treatment of viral infections
|
US20090048189A1
(en)
|
2007-08-15 |
2009-02-19 |
Genelabs Technologies, Inc. |
Tricyclic-nucleoside compounds for treating viral infections
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US20090318380A1
(en)
|
2007-11-20 |
2009-12-24 |
Pharmasset, Inc. |
2',4'-substituted nucleosides as antiviral agents
|
WO2009086192A1
(en)
|
2007-12-21 |
2009-07-09 |
Alios Biopharma, Inc. |
Biodegradable phosphate protected nucleotide derivatives and their use as cancer, anti viral and anti parasitic agents
|
WO2009146123A2
(en)
|
2008-04-03 |
2009-12-03 |
Spring Bank |
Compositions and methods for treating viral infections
|
PT2268642E
(pt)
|
2008-04-23 |
2015-06-02 |
Gilead Sciences Inc |
Análogos de carba-nulceósidos 1¿-substituídos para tratamento antiviral
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
WO2010002877A2
(en)
|
2008-07-03 |
2010-01-07 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
GB0815968D0
(en)
|
2008-09-03 |
2008-10-08 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
WO2010039548A2
(en)
|
2008-09-23 |
2010-04-08 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
KR20110104074A
(ko)
|
2008-12-23 |
2011-09-21 |
파마셋 인코포레이티드 |
퓨린 뉴클레오시드의 합성
|
CL2009002208A1
(es)
|
2008-12-23 |
2010-10-29 |
Gilead Pharmasset Llc |
Un compuesto (2s)-2-((((2r,3r,4r,5r)-5-(2-amino-6-etoxi-9h-purin-9-il)-4-fluoro-3-hidroxi-4-metiltetrahidrofuran-2-il)metoxi)(hidroxi)fosforilamino)propanoico, inhibidores de la replicacion de arn viral; composicion farmaceutica; y su uso en el tratamiento de infeccion por hepatitis c, virus del nilo occidental, entre otras.
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
SG172921A1
(en)
|
2009-01-09 |
2011-08-29 |
Univ Cardiff |
Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
JP2012517443A
(ja)
|
2009-02-06 |
2012-08-02 |
アールエフエス ファーマ,エルエルシー |
癌及びウイルス感染の治療のためのプリンヌクレオシド一リン酸プロドラッグ
|
ES2453078T3
(es)
|
2009-02-10 |
2014-04-03 |
Gilead Sciences, Inc. |
Análogos de carba-nucleósido para tratamiento antiviral
|
WO2010108135A1
(en)
|
2009-03-20 |
2010-09-23 |
Alios Biopharma, Inc. |
Protected nucleotide analogs
|
EA201190178A1
(ru)
|
2009-03-20 |
2012-06-29 |
Алиос Биофарма, Инк. |
Замещённые нуклеозидные и нуклеотидные аналоги
|
US20100297079A1
(en)
|
2009-05-20 |
2010-11-25 |
Chimerix, Inc. |
Compounds, compositions and methods for treating viral infection
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
EP2451980B1
(en)
|
2009-07-06 |
2014-05-21 |
TriLink BioTechnologies |
Chemically modified ligase cofactors, donors and acceptors
|
US8455451B2
(en)
|
2009-09-21 |
2013-06-04 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US7973013B2
(en)
|
2009-09-21 |
2011-07-05 |
Gilead Sciences, Inc. |
2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
|
US20100077085A1
(en)
|
2009-09-23 |
2010-03-25 |
Joseph Chyam Cohen |
Systems and method for configuring display resolution in a terminal server environment
|
AU2010302971B2
(en)
*
|
2009-09-29 |
2014-05-01 |
Janssen Products, L.P. |
Phosphoramidate derivatives of nucleosides
|
US8816074B2
(en)
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
MX2012005601A
(es)
|
2009-11-16 |
2012-08-01 |
Univ Georgia |
Nucleosidos carboxiclicos de 2'-fluoro-6'-metileno y metodos para tratar infecciones virales.
|
PT2528930E
(pt)
|
2010-01-28 |
2013-11-26 |
Hoffmann La Roche |
Nucleósidos de 4'-azido como compostos anti-vhc
|
CA2791630A1
(en)
|
2010-03-04 |
2011-09-09 |
Enanta Pharmaceuticals, Inc. |
Combination pharmaceutical agents as inhibitors of hcv replication
|
KR101715981B1
(ko)
|
2010-03-31 |
2017-03-13 |
길리애드 파마셋 엘엘씨 |
뉴클레오사이드 포스포르아미데이트
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
US8680071B2
(en)
|
2010-04-01 |
2014-03-25 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
TW201201815A
(en)
|
2010-05-28 |
2012-01-16 |
Gilead Sciences Inc |
1'-substituted-carba-nucleoside prodrugs for antiviral treatment
|
US20110306541A1
(en)
|
2010-06-10 |
2011-12-15 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
KR102108864B1
(ko)
|
2010-07-19 |
2020-05-12 |
길리애드 사이언시즈, 인코포레이티드 |
부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
|
TW201305185A
(zh)
|
2010-09-13 |
2013-02-01 |
Gilead Sciences Inc |
用於抗病毒治療之2’-氟取代之碳-核苷類似物
|
CA2812962C
(en)
|
2010-09-22 |
2020-03-31 |
Alios Biopharma, Inc. |
Azido nucleosides and nucleotide analogs
|
US20120070411A1
(en)
|
2010-09-22 |
2012-03-22 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
US8871737B2
(en)
|
2010-09-22 |
2014-10-28 |
Alios Biopharma, Inc. |
Substituted nucleotide analogs
|
WO2012048013A2
(en)
*
|
2010-10-06 |
2012-04-12 |
Inhibitex, Inc. |
Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections
|
ES2605433T3
(es)
|
2010-11-10 |
2017-03-14 |
Janssen Products, L.P. |
Fosforamidatos de espironucleósido oxetánico uracílico
|
EP2638054B1
(en)
|
2010-11-10 |
2014-12-03 |
Janssen Products, L.P. |
Uracyl spirooxetane nucleoside phosphoramidates
|
AR084044A1
(es)
|
2010-11-30 |
2013-04-17 |
Pharmasset Inc |
Compuestos 2’-espiro-nucleosidos
|
AU2011349844B2
(en)
|
2010-12-20 |
2017-06-01 |
Gilead Sciences, Inc. |
Combinations for treating HCV
|
CA2819041A1
(en)
|
2010-12-22 |
2012-06-28 |
Alios Biopharma, Inc. |
Cyclic nucleotide analogs
|
US9351989B2
(en)
|
2010-12-29 |
2016-05-31 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
US9156874B2
(en)
|
2011-01-03 |
2015-10-13 |
Nanjing Molecular Research, Inc. |
Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
|
CN103403014B
(zh)
|
2011-01-03 |
2016-07-06 |
河南美泰宝生物制药有限公司 |
O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途
|
WO2012125900A1
(en)
|
2011-03-16 |
2012-09-20 |
Enanta Pharmaceuticals, Inc. |
2'-allene-substituted nucleoside derivatives
|
CN103842369A
(zh)
|
2011-03-31 |
2014-06-04 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
CN103476783A
(zh)
|
2011-04-13 |
2013-12-25 |
吉里德科学公司 |
用于抗病毒治疗的1’-取代的嘧啶n-核苷类似物
|
US9156872B2
(en)
|
2011-04-13 |
2015-10-13 |
Merck Sharp & Dohme Corp. |
2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
CA2832449A1
(en)
|
2011-04-13 |
2012-10-18 |
Vinay GIRIJAVALLABHAN |
2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US9061041B2
(en)
*
|
2011-04-13 |
2015-06-23 |
Merck Sharp & Dohme Corp. |
2′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
WO2012158811A2
(en)
|
2011-05-19 |
2012-11-22 |
Rfs Pharma, Llc |
Purine monophosphate prodrugs for treatment of viral infections
|
EP2731433A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE ANALOGUES AND METHODS OF USE FOR THE TREATMENT OF VIRAL DISEASES
|
EP2731434A4
(en)
|
2011-07-13 |
2014-12-31 |
Merck Sharp & Dohme |
5'-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
|
US20140315850A1
(en)
|
2011-07-19 |
2014-10-23 |
Nanjing Molecular Research, Inc. |
2',3'-Dideoxy-2'-alpha-Fluoro-2'-beta-C-Methylnucleosides and Prodrugs Thereof
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
CA2847892A1
(en)
*
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013044030A1
(en)
|
2011-09-23 |
2013-03-28 |
Enanta Pharmaceuticals, Inc. |
2'-chloroacetylenyl substituted nucleoside derivatives
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
WO2013084165A1
(en)
|
2011-12-05 |
2013-06-13 |
Medivir Ab |
Hcv polymerase inhibitors
|
CN108409820A
(zh)
|
2011-12-20 |
2018-08-17 |
里博科学有限责任公司 |
作为hcv rna复制抑制剂的4′-叠氮基,3′-氟取代的核苷衍生物
|
WO2013092481A1
(en)
|
2011-12-20 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
|
US20140356325A1
(en)
|
2012-01-12 |
2014-12-04 |
Ligand Pharmaceuticals Incorporated |
Novel 2'-c-methyl nucleoside derivative compounds
|
MD20140134A2
(ro)
|
2012-05-22 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
WO2013177188A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
US9192621B2
(en)
|
2012-09-27 |
2015-11-24 |
Idenix Pharmaceuticals Llc |
Esters and malonates of SATE prodrugs
|
CN104936970A
(zh)
|
2012-10-08 |
2015-09-23 |
埃迪尼克斯医药公司 |
用于hcv感染的2′-氯核苷类似物
|
US9242988B2
(en)
|
2012-10-17 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
AR092959A1
(es)
|
2012-10-17 |
2015-05-06 |
Merck Sharp & Dohme |
Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
|
EP2909210A4
(en)
|
2012-10-17 |
2016-04-06 |
Merck Sharp & Dohme |
2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
EP2909222B1
(en)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
2',4'-bridged nucleosides for hcv infection
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
EP2920195A1
(en)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
D-alanine ester of rp-nucleoside analog
|
US20140205566A1
(en)
|
2012-11-30 |
2014-07-24 |
Novartis Ag |
Cyclic nucleuoside derivatives and uses thereof
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
WO2014124430A1
(en)
|
2013-02-11 |
2014-08-14 |
Emory University |
Nucleotide and nucleoside therapeutic compositions and uses related thereto
|
EP2970358B1
(en)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-deoxy nucleosides for the treatment of hcv
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
US20140271547A1
(en)
|
2013-03-13 |
2014-09-18 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
CN103848876B
(zh)
|
2013-03-25 |
2016-05-11 |
安徽贝克联合制药有限公司 |
一种核苷磷酰胺前药及其制备方法和其应用
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
WO2014204831A1
(en)
|
2013-06-18 |
2014-12-24 |
Merck Sharp & Dohme Corp. |
Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
US20150037282A1
(en)
|
2013-08-01 |
2015-02-05 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
US20160271162A1
(en)
|
2013-11-01 |
2016-09-22 |
Idenix Pharmacueticals, Llc |
D-alanine phosphoramide pronucleotides of 2'-methyl 2'-fluro guanosine nucleoside compounds for the treatment of hcv
|
US20160280729A1
(en)
|
2013-11-20 |
2016-09-29 |
Idenix Pharmaceuticals Llc |
Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
WO2015081133A2
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
Nucleotides for the treatment of liver cancer
|
CN103848877B
(zh)
|
2013-12-16 |
2016-08-24 |
安徽贝克联合制药有限公司 |
核苷环磷酸酯化合物及其制备方法和其应用
|
WO2015095305A1
(en)
|
2013-12-17 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
Production of cyclic phosphate, phosphoramidate, thiophosphate, and phosphonate nucleoside compounds
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
EP3113763A1
(en)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Solid prodrug forms of 2'-chloro-2'-methyl uridine for hcv
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|